We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The European Court of Justice has issued a significant final ruling
on a long-running case over conflicting exclusivity periods within the European
Union (EU) and the European Economic Area (EEA) trade bloc.
An agreement between Fonterra subsidiary, Lactose New Zealand, and GlaxoSmithKline
(GSK) will see New Zealand supply the world's largest user of inhalation grade
pharmaceutical lactose with half of its total yearly requirements.
Health Minister Ujjal Dosanjh says he's considering a ban on bulk exports of
drugs to the United States in order to head off potential drug shortages in
Canada.
Altachem Pharma announced that it has closed the second and last tranche of
the non-brokered private placement financing announced Dec. 10, 2004, with the
sale of an additional 4,200,000 units (the "Units") for gross proceeds
of $1,050,000.
Novartis AG has successfully
completed the EU Mutual Recognition Procedure (MRP) in 14 countries for Diovan
(valsartan) for the treatment of heart attack survivors.
Mexican drug regulator COFEPRIS claims that the advertising of widely-available
"miracle products" is coming under control, with promotional material
for 67 of the dubious treatments -- or roughly 90% of the total -- removed
from the market in recent months.
Local observers suggest that Poland's generics-dominated reimbursement
list and harsh pricing policy is discouraging the multinational research-based
sector.